News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SBP GROUP: Innovative Drug Naldemedine Approved for Marketing in Greater Bay Area
SBP GROUP (01177.HK) announced that Naldemedine, an innovative drug exclusively licensed by its subsidiary, Chia Tai Tianqing Pharmaceutical, was approved by the Guangdong Medical ...
Reset
Send
The window will close in 5 seconds
SBP GROUP: Innovative Drug Naldemedine Approved for Marketing in Greater Bay Area
Close
Recommend
18
Positive
24
Negative
9
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

SBP GROUP (01177.HK)  -0.040 (-0.671%)    Short selling $70.42M; Ratio 19.181%   announced that Naldemedine, an innovative drug exclusively licensed by its subsidiary, Chia Tai Tianqing Pharmaceutical, was approved by the Guangdong Medical Products Administration for an early launch in the Guangdong-Hong Kong-Macao Greater Bay Area for the treatment of opioid-induced constipation (OIC).
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-10 16:25.)

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.